Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer

Giornale Italiano di Dermatologia e Venereologia

Volumn 148, Issue 6, 2013, Pages 693-698

  Puviani, M ^a   Barcella, A ^b   Milani, M ^c  

^a Ospedale di Sassuolo   (Italy)

^b Servizio di Dermatologia   (Italy)

^c Direzione Medica ISDIN Italia ^*  (Italy)

Author keywords

Case reports; Keratosis, actinic; Sunscreening agents

Indexed keywords

DEOXYRIBODIPYRIMIDINE PHOTOLYASE; ERYFOTONA AK NMSC; PROTEIN P53; PYRIMIDINE DIMER; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACTINIC KERATOSIS; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; DEVICE SAFETY; DRUG DELIVERY DEVICE; DRUG SAFETY; FILM FORMING MEDICAL DEVICE; GENE EXPRESSION; HUMAN; KERATINOCYTE; MALE; MEDICAL DEVICE; NANOFILTER; NON MELANOMA SKIN CANCER; THERAPY EFFECT; TREATMENT DURATION; UPREGULATION;

AGED; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DEOXYRIBODIPYRIMIDINE PHOTO-LYASE; EAR; FACE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; KERATINOCYTES; KERATOSIS, ACTINIC; LIPOSOMES; MALE; MIDDLE AGED; SCALP; SKIN NEOPLASMS; SUNSCREENING AGENTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895786893     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg 1997;23:1009-19.
2. Marks R, Jolley D, Lectsas S, Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990;152:62-6. (Pubitemid 20036300)
3. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51. (Pubitemid 23295456)
4. Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP. Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. J Nucleic Acids 2010:592980.
5. Vink AA, Roza L. Biological consequences of cyclobutane pyrimidine dimers. J Photochem Photobiol 2001;65:101-4. (Pubitemid 34110723)
6. Griffiths HR, Mistry P, Herbert KE, Lunec J. Molecular and cellular effects of ultraviolet light-induced genotoxicity. Crit Rev Clin Lab Sci 1998;35:189-237. (Pubitemid 28370351)
7. Durbeej B, Eriksson LA. On the formation of cyclobutane pyrimidine dimers in UV-irradiated DNA: Why are thymines more reactive? Photochem Photobiol 2003;78:159-67.
8. Thoma F. Light and dark in chromatin repair: repair of UV-induced DNA lesions by photolyase and nucleotide excision repair. EMBO J 1999;18:6585-98.
9. Jans J, Schul W, Sert YG, Rijksen Y, Rebel H, Eker AP et al. Powerful skin cancer protection by a CPD-photolyase transgene. Curr Biol 2005;15:105-5.
10. Puig S Evaluation of the effects of Eryfotona® AK-NMSC a product containing photolyase and UV filters, to improve the subclinical cancerization field in AK patients. JAAD 2012;AB151.
11. Vidal S. Photolyase sunscreen decreases expression of p53 and Ki67 in comparison to standard 50 SPF. JAAD 2012;AB156.
12. Puig-Butillé JA, Malvehy J, Potrony M, Trullas C, Garcia-García F, Dopazo J et al. Role of CPI-17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters. Experimental Dermatology 2013;22:482-501.
13. Piaserico S, Milani M. Efficacia clínica della fotoliasi tópica dopo terapia fotodinámica in soggetti con cheratosi attinica: studio prospettico randomizzato intrapaziente. Giornale Italiano Dermatologia Venereologia 2012;147(s2):109.
14. Puviani M, Barcella A, Floris A, Milani M, Cavicchini S. Eryfotona AK-NMSC in the treatment of cancerization field in patients with actinic keratosis or non-melanoma skin cancer: A report of six cases. Gior Ital Dermatol Venereol 2013;148(S2):1-6.
15. Calzavara-Pinton P, Sala R, Arisi MC, Bussoletti C, Celleno L. Photobiology, photodermatology and sunscreens: a comprehensive overview. G Ital Dermatol Venereal 2013;148:89-106.
16. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg 1997;23:1009-19.
17. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-3.
18. Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E et al. Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol 2007;156(Suppl 3):13-7. (Pubitemid 46632516)
19. Sanmartin O, Guillen C. Images in clinical medicine. fluorescence diagnosis of subclinical actinic keratoses. N Engl J Med 2008;358:e21. (Pubitemid 351656460)
20. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1, pt 2):4-7.
21. Slaughter D P, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium. Cancer (Phila.) 1995;6:963-8.
22. de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses [published correction appears in Br J Dermatol 2008;158:873. Br J Dermatol 2007;156:222-30.
23. Rosen T. Future paradigms of actinic keratosis therapy. Skin & Aging 2009;(Suppl):12-5.
24. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995;32:95-8.